NCT00660452

A Phase III Study to Assess Efficacy and Safety of STALORAL® 300 IR Sublingual Immunotherapy (SLIT) in Asthmatic Patients Allergic to House-dust Mites

A Randomised, Double-blind, Placebo-controlled, Multi-centre, Phase III Study to Assess Efficacy and Safety of STALORAL® 300 IR Sublingual Immunotherapy (SLIT) in Chinese Asthmatic Patients Allergic to House-dust Mites

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 484 (actual)
• Sponsor: Stallergenes Greer · Industry
• Sex: All
• Age: 16 Years – 50 Years
• Healthy volunteers: Not accepted

Summary

A phase III study to assess the efficacy and safety of sublingual immunotherapy with STALORAL dust mites solution compared with placebo for reduction of asthma symptoms.

Conditions

• Allergy

Interventions

Type	Name	Description
DRUG	Staloral	Sublingual immunotherapy with Staloral dust mites solution

Timeline

• Start date: 2007-10-01
• Primary completion: 2009-07-01
• Completion: 2009-07-01
• First posted: 2008-04-17
• Last updated: 2011-10-12

Locations

1 site across 1 country: China